STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Companies Large-Cap
drugs

Breakthrough in Hemophilia A Treatment: Pfizer’s Gene Therapy Shows Promising Results

byLiliana Vida
July 24, 2024
in Large-Cap, Pharmaceuticals
Reading Time: 3 mins read
Share on TwitterShare on LinkedIn

AFFINE Study Demonstrates Superiority of Giroctocogene Fitelparvovec Over Routine Prophylaxis

Pfizer (PFE) recently announced encouraging results from the Phase 3 AFFINE study (NCT04370054), evaluating giroctocogene fitelparvovec, an investigational gene therapy, for adults with moderately severe to severe hemophilia A. This pivotal study underscores the transformative potential of gene therapy in providing effective bleed protection and reducing the treatment burden for patients.

Promising Efficacy and Safety Results

The AFFINE study met its primary objective, demonstrating both non-inferiority and superiority in total annualized bleeding rate (ABR) compared to routine Factor VIII (FVIII) replacement prophylaxis. Patients receiving a single 3e13 vg/kg dose of giroctocogene fitelparvovec showed a statistically significant reduction in mean total ABR from 4.73 pre-infusion to 1.24 post-infusion (one-sided p-value=0.0040).

Moreover, key secondary endpoints were achieved, further highlighting the superiority of giroctocogene fitelparvovec. An impressive 84% of participants maintained FVIII activity above 5% at 15 months post-infusion (one-sided p-value = 0.0086), with most participants reaching FVIII activity levels of at least 15%. Additionally, the mean treated ABR saw a dramatic reduction of 98.3%, from 4.08 pre-infusion to just 0.07 post-infusion (one-sided p-value < 0.0001). Notably, only one participant (1.3%) resumed prophylaxis post-infusion.

Safety Profile and Tolerability

Giroctocogene fitelparvovec was generally well tolerated in the AFFINE study. While 49.3% of participants experienced transient elevated FVIII levels ≥150%, these occurrences did not impact the therapy’s efficacy or safety. Serious adverse events were reported in 15 patients (20%), with 13 events in 10 patients (13.3%) deemed related to the treatment. These adverse events typically resolved with appropriate clinical management.

Professor Andrew Leavitt M.D., AFFINE lead investigator and Director of the Adult Hemophilia Treatment Center at the University of California, San Francisco, remarked, “The physical and emotional burden of frequent IV infusions or injections cannot be underestimated for people with hemophilia A. These positive results from the AFFINE trial show the transformative potential of giroctocogene fitelparvovec in providing superior bleed protection while easing the treatment burden.”

A Glimpse into the Future of Hemophilia A Treatment

Giroctocogene fitelparvovec represents a novel, investigational gene therapy combining a bio-engineered AAV6 capsid with a modified B-domain deleted human coagulation FVIII gene. The goal is to enable patients to produce FVIII endogenously following a single infusion, thereby offering long-term bleed protection and significantly reducing the need for routine prophylaxis with IV infusions or injections.

Dr. James Rusnak, Senior Vice President, Chief Development Officer of Internal Medicine and Infectious Diseases at Pfizer, expressed his enthusiasm for the AFFINE study results. “We are very pleased with the positive outcomes from the Phase 3 AFFINE study, demonstrating the safety and efficacy of our one-time gene therapy candidate for hemophilia A. We look forward to advancing this innovation to address the medical and treatment burden associated with frequent IV infusions or injections.”

Participants in the AFFINE study initially enrolled in a lead-in study (NCT03587116) and, upon successful completion, received a one-time dose of giroctocogene fitelparvovec by IV infusion. Patients will be evaluated over five years, with long-term follow-up extending up to 15 years.

Regulatory Pathways and Future Prospects

Further analyses of the full Phase 3 dataset are ongoing, and additional data will be presented at upcoming medical conferences. Giroctocogene fitelparvovec has received Fast Track and Regenerative Medicine Advanced Therapy designations from the U.S. FDA, along with Orphan Drug designations in the U.S. and the EU. Pfizer will engage with regulatory authorities in the coming months to discuss these promising results.

Pfizer’s commitment to advancing hemophilia treatment is evident with its recent FDA approval of BEQVEZ™ (fidanocogene elaparvovec) for hemophilia B and ongoing regulatory reviews for marstacimab, a novel subcutaneous therapy for hemophilia A and B. The successful development of giroctocogene fitelparvovec could mark a significant milestone in improving the quality of life for people living with hemophilia A.

Read original press release:here

You might like this article:Perfect Corp. Posts Strong Q2 2024 Financial Results

Tags: BreakingGrowthMoversNewsPharmaceuticalsStock Market
Previous Post

Perfect Corp. Posts Strong Q2 2024 Financial Results

Next Post

The CRWD Crisis: An In-depth Look at the Recent IT Outage and Its Repercussions

Related Posts

trading-chart-2

Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth

byLuca Blaumann
July 30, 2025
0

Record Automotive Revenue and $3.8 Billion Returned to Shareholders Highlight Robust Quarter Qualcomm (QCOM) delivered solid third-quarter fiscal 2025 results,...

Palo Alto Networks Eyes $20B Deal for CyberArk

byLuca Blaumann
July 29, 2025
0

Potential Acquisition Could Reshape the Cybersecurity Landscape Palo Alto Networks (PANW) is reportedly in advanced discussions to acquire CyberArk Software...

FCC Approves $8B Paramount-Skydance Merger Amid Political Controversy

byLuca Blaumann
July 25, 2025
0

Deal includes CBS, Nickelodeon, and Paramount Pictures; DEI policies rejected as scrutiny mounts The Federal Communications Commission (FCC) on Thursday...

Next Post
trading-chart-3

The CRWD Crisis: An In-depth Look at the Recent IT Outage and Its Repercussions

Latest News

Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth

Palo Alto Networks Eyes $20B Deal for CyberArk

AMD and Amazon: Two Titans Poised for Explosive Growth

FCC Approves $8B Paramount-Skydance Merger Amid Political Controversy

FAA Keeps Boeing 737 MAX Production Cap in Place Amid Ongoing Oversight

Based on Your Interest

Large-Cap

Intel Beats on Revenue, Misses on Earnings; Cuts Workforce by 15%

July 24, 2025
trading-chart-2
Brokerages

Accelerant Soars in NYSE Debut, Valued at $6.4 Billion

July 24, 2025
investing
Distributor

GoPro and Krispy Kreme Surge as Meme Stock Frenzy Reignites

July 23, 2025

Recommended

Electrical Equipment

GE Vernova Soars to Record High on Raised Cash Flow Outlook

July 23, 2025
Auto Manufacturers

Earnings Season Surprises: Coca-Cola Delivers, GM Struggles Under Tariff Pressure

July 22, 2025
Entertainment

Trump Media Stock Rises After $2 Billion Bitcoin Bet

July 21, 2025
Biotechnology

ProMIS Neurosciences Soars 160% After FDA Fast Track Designation for Alzheimer’s Drug

July 21, 2025
Bitcoin

Michael Saylor’s Strategy Now Holds Over 3% of All Bitcoin Ever Minted

July 21, 2025
Stoxpo

Follow us on social media:

Highlights

  • Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth
  • Palo Alto Networks Eyes $20B Deal for CyberArk
  • AMD and Amazon: Two Titans Poised for Explosive Growth
  • FCC Approves $8B Paramount-Skydance Merger Amid Political Controversy
  • FAA Keeps Boeing 737 MAX Production Cap in Place Amid Ongoing Oversight

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

trading-chart-2

Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth

July 30, 2025

Palo Alto Networks Eyes $20B Deal for CyberArk

July 29, 2025
trading-chart

AMD and Amazon: Two Titans Poised for Explosive Growth

July 28, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?